
Meena Savur Moran, MD, professor, therapeutic oncology, and director of the radiation therapy breast program, Smilow Cancer Hospital at Yale-New Haven, discusses the margin guidelines that have been identified in breast conservation.

Meena Savur Moran, MD, professor, therapeutic oncology, and director of the radiation therapy breast program, Smilow Cancer Hospital at Yale-New Haven, discusses the margin guidelines that have been identified in breast conservation.

Francisco Esteva, director, breast medical oncology program, Perlmutter Cancer Center, NYU Langone Medical Center, discusses the findings of a biosimilar trastuzumab study in patients with HER2-positive breast cancer.

Erica Bell, PhD, assistant professor, radiation oncology, Ohio State University Comprehensive Cancer Center, discusses the status of biomarker research in low-grade gliomas.

Richard S. Finn, MD, an associate professor of Medicine at the UCLA David Geffen School of Medicine, discusses the role of immunotherapy in the treatment of liver cancer.

Morris Sherman, MD, PhD, professor of Medicine at University of Toronto, discusses the process of conducting a screening program for liver cancer.

Don Bergstrom, MD, PhD, chief medical officer, Mersana Therapeutics, discusses the future of XMT-1536 in the treatment of ovarian cancer and non-small cell lung cancer (NSCLC).

Yvonne Saenger, MD, director, melanoma immunotherapy, Columbia University Medical Center, discusses the impacts of chemotherapy and immunotherapy in melanoma.


Heinz Gisslinger, MD, Medical University of Vienna, discusses new compounds in polycythemia vera (PV).

Naval Daver, MD, assistant professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses agents being investigated in acute myeloid leukemia (AML).

Alexander I. Sankin, MD, assistant professor of Urology at Montefiore Medical Center at the Albert Einstein College of Medicine, discusses the differences between the recently defined checkpoint HHLA2 and PD-L1 expression in urothelial tumors, as well as next steps in this space.

Luke Nordquist, MD, FACP, a urologic medical oncologist and CEO of the Urology Cancer Center and GU Research Network, gives an overview of the Alpharadin in Symptomatic Prostate Cancer Patients (ALSYMPCA) study, and he discusses ongoing trials examining the use of radium-223 dichloride (Xofigo) in metastatic castration-resistant prostate cancer (mCRPC).

Axel Grothey, MD, medical oncologist, Department of Oncology, Mayo Clinic, discusses the role of sidedness in tumor location in colorectal cancer.

Leslie M. Randall, MD, associate professor of Gynecology/Oncology, University of California Irvine, discusses the use of olaparib as maintenance therapy in the treatment of patients with ovarian cancer.

James Jett, MD, professor of Medicine Emeritus, National Jewish Health, discusses the use of endobronchial ultrasound (EBUS) in the diagnosis of lung cancer.

Dmitriy Zamarin, MD, PhD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the role of in situ tumor vaccination across various types of cancer.

Adam Bass, MD, assistant professor of Medicine, Harvard Medical School, physician/scientist, Dana-Farber Cancer Institute, discusses the importance of individualizing treatments for patients with gastric/esophageal cancer.

Sundar Jagannath, MD, director, Multiple Myeloma Program, Tisch Cancer Institute at Mount Sinai Hospital, discusses the role of stem-cell transplant in the management of multiple myeloma.

Raffaele Califano, MD, consultant in medical oncology, The Christie Clinic, University Hospital of South Manchester, discusses the recent investigations into the use of immune checkpoint blockades in small cell lung cancer.

Madhav Dhodapkar, MBBS, clinical research program leader, Hematology Program, Yale Cancer Center, discusses the evolving field of immuno-oncology and the significant benefits it stands to have for patients.

Kanwal Raghav, MBBS, MD, assistant professor, Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the clinical application of the data on HER2 gene amplification in patients with metastatic colorectal cancer, as well as the benefits of using a therapy that combines trastuzumab and pertuzumab.

Saeed Rafii, MD, PhD, medical director, Sarah Cannon Research Institute, United Kingdom, discusses the mechanism of action of the PD-1 antibody durvalumab in a phase I/II dose-escalation and dose-expansion study in the treatment of patients with metastatic urothelial bladder cancer. He also discusses the next steps in this line of research.

Heather Wakelee, MD, associate professor of Medicine (Oncology), Stanford University Medical Center, discusses the evolving role of bevacizumab (Avastin) in the treatment of patients with non–small cell lung cancer.

Rose K. Lai, MD, clinical associate professor of Neurology, University of Southern California, discusses the many risk factors that can be associated with glioma.

Maurie Markman, MD, president, Medicine and Science, Cancer Treatment Centers of America, discusses the benefits and risks of performing a bilateral salpingo-oophorectomy as a treatment for patients with ovarian cancer.

Linda Bosserman, MD, medical oncologist, City of Hope, discusses the effects that payment reform may have on clinical practice in oncology.

Eleftherios P. Mamounas, MD, surgical oncologist, UF Health Cancer Center - Orlando Health, compares mastectomy with breast conservation in the surgical management of breast cancer.

Christopher E. Barbieri, MD, PhD, surgeon, researcher in prostate cancer, Sandra and Edward Meyer Cancer Center at Weill Cornell Medicine and New-York Presbyterian, discusses the role of PARP inhibitors in castration-resistant prostate cancer.

George D. Demetri, MD, senior vice president for Experimental Therapeutics at the Dana-Farber Cancer Institute, professor of Medicine at Harvard Medical School, and co-director of the Ludwig Center at Harvard, discusses the relevance of sarcoma in the converging worlds of targeted therapies and immuno-oncology.

Richard M. Stone, MD, Program Director, Adult Leukemia Program, Dana-Farber Cancer Institute, discusses the CALGB 10603 trial, which explored the use of midostaurin as a treatment for patients with FLT3-mutated acute myeloid leukemia.